Brief: Adaptimmune, Bellicum Pharma collaborate to evaluate next-generation T-cell therapies
19/12/2016 12:30
Dec 19 (Reuters) - Adaptimmune Therapeutics Plc ADAP.O
* Adaptimmune and Bellicum Pharmaceuticals enter a strategic
collaboration to evaluate next-generation T-cell therapies
* Adaptimmune Therapeutics - Based on results from
preclinical proof-of-concept phase,cos expect to progress to
two-target co-development,co-commercialization phase
* Adaptimmune Therapeutics - Co's to evaluate Bellicum's
GOTCR technology with Adaptimmune's affinity-optimized spear
T-cells to create TCR product candidates
Source text for Eikon: urn:newsml:reuters.com:*:nGNXNNOABa
Further company coverage: ADAP.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview